Professor John Snowden
Professor John Snowden, BSc (Hons), MBChB, MD, FRCP (London), FRCP (Edinburgh), FRCPath, DTM&H
Professor John Snowden graduated from the University of Leeds in 1989 and trained in Internal Medicine and Haematology in the UK, New Zealand and Australia. In 2002, he was appointed as Consultant Haematologist & Director of Blood and Marrow Transplantation (BMT) at Sheffield Teaching Hospitals NHS Foundation Trust and holds Honorary Professorships with the University of Sheffield and University College London.
He is the current Secretary to the European Society for Blood and Marrow Transplantation (EBMT) and the immediate Past-President of the British Society for BMT and Cellular Therapy (BSBMTCT).
Dr Majid Kazmi
HSCT for MS in the UK and the power of patient advocacy; a 15 year perspective.
BmedBiol (honours) MB ChB (with commendation) FRCP(UK) FRCPath
Dr Kazmi qualified from the University of Aberdeen in 1991 with Commendation, he is a member of European group for Blood and Marrow Transplantation (EBMT), International Myeloma Society, Faculty of Medical Leadership and Management and American Society of Haematology (ASH). He has been a consultant in Haemato-oncology since 2001 at Guy’s & St Thomas’ NHS Trust and King’s College Hospital NHS Trust.
He is currently Director of Innovation for Cancer and Surgery at Guy’s & St Thomas’ NHS Trust. He was previously Chief of Cancer services and Clinical Director for Oncology and Haematology.
Dr Richard K Burt
RRMS and Progressive MS
Dr Burt is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University, and CEO of Genani biotechnology. He endeavored for thirty-five years, first with animal models then with some of the world’s first clinical trials, to bring the field of stem cell and cellular therapy to the patient’s bedside. Dr. Burt has published more than 145 mostly first author articles and is the Editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institute of Health (NIH) $10,000,000 multi-center contract to develop stem cell clinical trials for autoimmune diseases.
Professor Gavin Giovannoni
Treating MS beyond no evident inflammatory activity (NEIDA): why AHSCT should be an option available to people with MS
Gavin Giovannoni is an academic neurologist at the Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London.
His current research is focused on the Epstein-Barr virus as a possible cause of multiple sclerosis, MS-related neurodegeneration, biomarker discovery & validation, and MS clinical outcomes.
Dr. Denis A. Fedorenko
The Modern Concept of Hematopoietic Stem Cell Transplantation for Multiple sclerosis
MD, PhD, Associate professor
Pirogov’s National Medical Surgical Center. Department hematology and Cellular Therapy named after A. Maximov.
D. Fedorenko graduated from Medical Military Academy in 1999 (MD). 1999 – 2004 postgraduate student in department Hematology and Clinical Immunology, Medical Military Academy. 2016 - PhD Comprehensive outcome assessment of HSCT effectiveness in lymphoma and multiple sclerosis patients
Professor Guillermo J. Ruiz-Argüelles
HSCT for multiple sclerosis. Clinica Ruiz experience
Professor Guillermo J. Ruiz-Argüelles is head of HSCT program at Clínica Ruiz México. He is a board certified hematologist and internal medicine specialist, He did a Post-doctoral research fellowship in the Department of Hematology of the Mayo Clinic and subsequently was elected as Mayo Clinic Distinguished Alumnus. He owns a Doctor Honoris Causa Degree by the Universidad Autonoma de San Luis Potosi. Member of the National Academy of Medicine, National Research System, level III (highest). Master of the American College of Physicians, fellow of the Royal College of Physicians and Surgeons of Glasgow, of the American Society of Hematology and of the Royal College of Physicians of London.
Challenging MS Myths in Mainstream Media
Mathew Embry, the Founder of MS Hope and an advocate of nutrition, optimal vitamin D, exercise and HSCT (Hematopoietic Stem Cell Transplantation), is supporting AIMS by speaking to further their efforts in creating exposure for this treatment. He believes that raising awareness about HSCT is crucial so that patients are informed about this powerful method to halt the progression of Multiple Sclerosis (MS) compared to conventional medications.
The Underrepresented: How to make MS Research and Clinical Trials more inclusive for the black
I am a mother of two, a 7 year MS Warrior and a Multiple Sclerosis (MS) advocate for the black MS community. I am also the Founder of a non-profit patient organisation called “The Nerve of My Multiple Sclerosis.”
The Lion, The Witch and the Wardrobe
Indu feels privileged to be asked to present something at the AIMS Summit as she feels closely aligned to their cause – which is supporting people with MS to live to their best, to find the best treatment and to empower them to access such treatments.
I was diagnosed with PPMS in 2009. I found out about HSCT by searching online, but my neurologist was very dismissive, despite no other treatment being available at that time. My condition was deteriorating fast, so when I was offered HSCT by Dr Fedorenko I was very grateful to accept and had treatment in Moscow in 2014. My EDSS was halted at 5.5 to 6.0 and remains that way nine years later.
Personal Experience of HSCT
Caroline Wyatt reported on war and global affairs for over 25 years as a foreign correspondent for BBC News, based in Berlin, Bonn, Moscow and Paris, travelling to report on wars and uprisings ranging from Kosovo, Afghanistan, Iraq, Chechnya and the wider Middle East.
Personal Experience of HSCT
Robert Douglas-Fairhurst is a Professor of English Literature and a Fellow of Magdalen College, Oxford. His books include Becoming Dickens (2011), which was awarded the Duff Cooper Prize, The Story of Alice (2015), which was shortlisted for the Costa Prize, and Metamorphosis: A Life in Pieces (2023).
Noëlle Tassy (EBMT Patient Advocacy Committee member)
Autologous HSCT in multiple sclerosis: patients' perspective before, during and after treatment
Noëlle Tassy has had multiple sclerosis for more than 30 years and over the past decade the disease has had a major impact on her life. She received 2 HSCT (2017 in France - 2019 in Russia) which succeeded in stopping MS progression but she keeps facing severe motor sequelae.